Volume 11 Supplement 1

16th Interntional Conference on Human Retroviruses: HTLV and Related Viruses

Open Access

Colostrum replacer and bovine leukaemia virus sero-positivity

  • Bhudipa Choudhury1Email author,
  • Christopher Finnegan1,
  • Jean-Pierre Frossard1,
  • Chris Venables1 and
  • Falko Steinbach1
Retrovirology201411(Suppl 1):P59

https://doi.org/10.1186/1742-4690-11-S1-P59

Published: 7 January 2014

Bovine Leukemia Virus (BLV), a Deltaretrovirus in the Retroviridae family, is the causative agent of Enzootic Bovine Leucosis (EBL). Whilst EBL is still endemic in the Americas and Eastern Europe, most Western European countries are disease free in accordance with European Union legislation e.g. Great Britain has held EBL-free status since 1999. BLV infection is life-long and the presence of antibody and integrated proviral DNA are indicators of exposure to the virus.Screening for antibodies is the primary means of diagnosis. Here we present three case reports of animals which tested BLV antibody positive. As there was no evidence that the animals or their in-contacts were infected with BLV the result was somewhat confusing. Investigation revealed that the animals had been fed a colostrum replacer that was produced outside of Great Britain. As BLV is endemic in some countries, it was considered that BLV antibodies may have been present in the colostrum replacer and thus passively acquired resulting in BLV sero-positivity. The hypothesis was supported by the declining serological antibody titre seen on serial blood sampling. We present data on the serological and molecular testing conducted on the animals and product in support of the hypothesis. The above mentioned cases were all linked by the same brand of colostrum replacer; in addition we provide data derived from the investigation of colostrum replacers from other manufacturers. The policy and International Trade implications will also be discussed.

Authors’ Affiliations

(1)
Department of Virology, AHVLA

Copyright

© Choudhury et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement